RecruitingPhase 2NCT07123727

A Study to Examine Anktiva for the Treatment of COVID-19.

Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID

Sponsor

ImmunityBio, Inc.

Enrollment

40 participants

Start Date

Sep 4, 2025

Study Type

INTERVENTIONAL

Conditions

Long COVID Long COVID Syndrome Long Covid 19

Summary

This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing Anktiva (also known as N-803), an immune-boosting drug, to see if it can help people recovering from COVID-19, particularly those experiencing lingering symptoms or complications. **You may be eligible if...** - You are 18–69 years old - You have had at least one confirmed COVID-19 infection (confirmed by a positive test such as PCR or rapid antigen test) **You may NOT be eligible if...** - You have never had a confirmed positive COVID-19 test (suspected but unconfirmed infections are not sufficient) - You are 70 years or older - You have certain immune conditions or other serious health issues that could interfere - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.